Abrogation of the Hematological and Biological Activities of the Interleukin-3/Granulocyte-Macrophage Colony-Stimulating Factor Fusion Protein PIXY321 by Neutralizing Anti-PIXY321 Antibodies in Cancer Patients Receiving High-Dose Carboplatin

MLA

Miller, Langdon L., et al. “Abrogation of the Hematological and Biological Activities of the Interleukin-3/Granulocyte-Macrophage Colony-Stimulating Factor Fusion Protein PIXY321 by Neutralizing Anti-PIXY321 Antibodies in Cancer Patients Receiving High-Dose Carboplatin.” Blood, vol. 93, no. 10, May 1999, pp. 3250–58. EBSCOhost, https://doi.org/10.1182/blood.V93.10.3250.410k35_3250_3258.

APA

Miller, L. L., Korn, E. L., Stevens, D. S., Janik, J. E., Gause, B. L., Kopp, W. C., Holmlund, J. T., Curti, B. D., Sznol, M., Smith, J. W., Urba, W. J., Donegan, S. E., Watson, T. M., & Longo, D. L. (1999). Abrogation of the Hematological and Biological Activities of the Interleukin-3/Granulocyte-Macrophage Colony-Stimulating Factor Fusion Protein PIXY321 by Neutralizing Anti-PIXY321 Antibodies in Cancer Patients Receiving High-Dose Carboplatin. Blood, 93(10), 3250–3258. https://doi.org/10.1182/blood.V93.10.3250.410k35_3250_3258

Chicago

Miller, Langdon L., Edward L. Korn, Diane S. Stevens, John E. Janik, Barry L. Gause, William C. Kopp, Jon T. Holmlund, et al. 1999. “Abrogation of the Hematological and Biological Activities of the Interleukin-3/Granulocyte-Macrophage Colony-Stimulating Factor Fusion Protein PIXY321 by Neutralizing Anti-PIXY321 Antibodies in Cancer Patients Receiving High-Dose Carboplatin.” Blood 93 (10): 3250–58. doi:10.1182/blood.V93.10.3250.410k35_3250_3258.